Skip to main content
. 2018 Apr 9;4(1):e000667. doi: 10.1136/rmdopen-2018-000667

Figure 2.

Figure 2

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour necrosis factor inhibitor (TNF-i), patients with rheumatoid arthritis (RA) naive to treatment and patients with psoriatic arthritis (PsA) naive to treatment. (A) CD68 (red)/CD21 (brown) staining of ST from patient with IBD with onset of peripheral arthritis under TNF-i treatment. (B) CD68 (red)/CD21 (brown) staining of ST from patient with RA naive to treatment. (C) CD68 (red)/CD21 (brown) staining of ST from patient with PsA naive to treatment (magnification 20× and 40× for the corresponding insert). (D) Lining and sublining IHC score for CD68+ and (E) CD21+ cells in patients with IBD (n=10) with onset of peripheral arthritis under TNF-i, patients with RA naive to treatment (n=15) and patients with PsA naive to treatment (n=12). (F) CD3 (red)/CD20 (brown) staining of ST from patient with IBD with onset of peripheral arthritis under TNF-i treatment. (G) CD3 (red)/CD20 (brown) staining of ST from patient with RA naive to treatment. (H) CD3 (red)/CD20 (brown) staining of ST from patient with PsA naive to treatment (magnification 20× and 40× for the corresponding insert). (I) Lining and sublining IHC score for CD20+ (lining IHC CD20 score in patients with RA naive to treatment vs patients with PsA naive to treatment, *p<0.05; sublining IHC CD20 score in patients with RA naive to treatment vs patients with PsA naive to treatment, *p<0.05) and (J) CD3+ cells in patients with IBD (n=10) with onset of peripheral arthritis under TNF-i, patients with RA naive to treatment (n=15) and patients with PsA naive to treatment (n=10).